Gain Therapeutics, Inc.
GANX
$3.32
$0.268.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 8.72% | -38.17% | -10.04% | -49.10% | 9.24% |
| Gross Profit | -8.72% | 38.17% | 10.04% | 49.10% | -9.24% |
| SG&A Expenses | 5.58% | -37.28% | 12.70% | 3.58% | -25.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.40% | -37.76% | -0.13% | -24.37% | -8.68% |
| Operating Income | -7.40% | 37.76% | 0.13% | 24.37% | 8.68% |
| Income Before Tax | -5.82% | 30.39% | -10.90% | 30.70% | 4.73% |
| Income Tax Expenses | 4,893.64% | 11,666.67% | 405.03% | 3,380.69% | -48.84% |
| Earnings from Continuing Operations | -17.81% | 28.66% | -12.85% | 20.23% | 4.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.81% | 28.66% | -12.85% | 20.23% | 4.93% |
| EBIT | -7.40% | 37.76% | 0.13% | 24.37% | 8.68% |
| EBITDA | -7.39% | 37.80% | 0.16% | 24.38% | 8.74% |
| EPS Basic | 10.70% | 54.81% | 29.29% | 56.76% | 54.48% |
| Normalized Basic EPS | 19.73% | 55.89% | 30.53% | 62.45% | 54.39% |
| EPS Diluted | 10.70% | 54.81% | 29.29% | 56.76% | 54.48% |
| Normalized Diluted EPS | 19.73% | 55.89% | 30.53% | 62.45% | 54.39% |
| Average Basic Shares Outstanding | 31.91% | 57.90% | 59.55% | 84.46% | 108.89% |
| Average Diluted Shares Outstanding | 31.91% | 57.90% | 59.55% | 84.46% | 108.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |